Eli Lilly's Zepbound Likely to Continue Uptake Despite CVS Decision, Truist Says
In This Article:
Eli Lilly's (LLY) Zepbound is expected to continue uptake despite CVS Health's (CVS) decision to dro
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.